Cel Limiting factors in pharmaceutical industry are related to organic solvent use in the production of drug systems, which generate waste streams and form toxic traces in the drug systems that often promote drug degradation. The solvent problems have increased with the development of drug delivery systems. Besides this, the applicability of several drug systems is restricted due to crystal habit and particle size distribution. Supercritical Fluid technology using compressed carbon dioxide does not have the drawback of forming contamination traces in drugs. Because of the additional degree of freedom related to the density of carbon dioxide, when either used as solvent or as anti-solvent, the technology is able to produce better designed pharmaceutical products, either simple drugs or complex encapsuled particles. Supercritical fluid technology does not create waste streams and has the advantage that the drug system is directly dry after depressurization.WP I- Description of six drug systems - Report concerning drugs, materials, conditions, fluids and class of SC process;WP II- Evaluation of bench scale facilities: RESS, SAS and impregnation - Manuals on the bench scale facilities, including GMP compliance - Report on single solute precipitation by RESS and SAS;WP III- Report on impregnation of biocompatible polymers with drugs using SCF - Report on the production of drugs using RESS and SAS, including protocols for the production of specific particles;WP IV - Process flow sheets to manufacture solvent free drug systems using SCF techniques for three selected industrial drug systems - Final report on the production of the three selected products containing:1) Process evaluation 2) Costs comparison 3) Product comparisonWP V- Final evaluation on product and marketing aspects of the three selected drug systems.This includes information regarding:- the drug release profile;- the required amount of drug;- therapy and administration;- marketing prospects. Dziedzina nauki medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsnatural scienceschemical sciencespolymer sciences Program(-y) FP5-GROWTH - Programme for research technological development and demonstration on "Competitive and sustainable growth 1998-2002" Temat(-y) 1.1.3.-1. - Key Action Innovative Products, Processes and Organisation Zaproszenie do składania wniosków Data not available System finansowania CSC - Cost-sharing contracts Koordynator CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Wkład UE Brak danych Adres Rue Paul Bert 27 Raoux-Cassin Délégué régional adj 94204 IVRY-SUR-SEINE Francja Zobacz na mapie Koszt całkowity Brak danych Uczestnicy (6) Sortuj alfabetycznie Sortuj według wkładu UE Rozwiń wszystko Zwiń wszystko CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS Hiszpania Wkład UE Brak danych Adres 3,Juan de la Cierva 3 28006 MADRID Zobacz na mapie Koszt całkowity Brak danych DELFT UNIVERSITY OF TECHNOLOGY Niderlandy Wkład UE Brak danych Adres Lorentzweg 1 2628 CJ DELFT Zobacz na mapie Koszt całkowity Brak danych FEYECON Niderlandy Wkład UE Brak danych Adres Javakade, 192 1019 RW AMSTERDAM Zobacz na mapie Koszt całkowity Brak danych FORNIX BIOSCIENCES N.V. Niderlandy Wkład UE Brak danych Adres Vijzelweg 11 8243 PM LELYSTAD Zobacz na mapie Koszt całkowity Brak danych SEPAREX EQUIPMENTS S.A. Francja Wkład UE Brak danych Adres Rue Jacque Monod, 5 54250 CHAMPIGNEULLES Zobacz na mapie Koszt całkowity Brak danych SOCIEDAD ESPANOLA DE CARBUROS METALLICOS SA Hiszpania Wkład UE Brak danych Adres Poligono Zona Franca 14-20 08038 BARCELONA Zobacz na mapie Koszt całkowity Brak danych
